by | May 5, 2024 | Publications
Ann Hematol. 2024 May 4. doi: 10.1007/s00277-024-05784-y. Online ahead of print. NO ABSTRACT PMID:38702445 | DOI:10.1007/s00277-024-05784-y
by | May 5, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Apr 7:S2152-2650(24)00149-6. doi: 10.1016/j.clml.2024.04.001. Online ahead of print. ABSTRACT BACKGROUND AND PURPOSE: Renal impairment (RI) confers adverse prognosis in myeloma; its reversal and avoidance of dialysis are crucial. We...
by | May 5, 2024 | Publications
Blood Cancer J. 2024 May 3;14(1):78. doi: 10.1038/s41408-024-01059-x. NO ABSTRACT PMID:38702349 | DOI:10.1038/s41408-024-01059-x
by | May 4, 2024 | Publications
STAR Protoc. 2024 May 2;5(2):103060. doi: 10.1016/j.xpro.2024.103060. Online ahead of print. ABSTRACT Preservation of fine cellular details of semi-adherent or suspension cells for imaging by immunofluorescence is challenging. This protocol enables staining of...
by | May 4, 2024 | Publications
Medicine (Baltimore). 2024 May 3;103(18):e38003. doi: 10.1097/MD.0000000000038003. ABSTRACT This study aims to investigate the ability of bone marrow imaging using third-generation dual-energy computed tomography (CT) virtual noncalcium (VNCa) to differentiate between...
by | May 4, 2024 | Publications
J Clin Oncol. 2024 May 3:JCO2300934. doi: 10.1200/JCO.23.00934. Online ahead of print. ABSTRACT PURPOSE: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by...